Chonsat 100 mg/ml 10 pcs. ampoules solution for intramuscular injection 1 ml

Degenerative-dystrophic diseases of the joints and spine:

• osteoarthritis of peripheral joints;

• intervertebral osteochondrosis and osteoarthritis. For accelerating the formation of callus in fractures.

The drug is administered intramuscularly at a dose of 1 ml (100 mg) every other day. With good tolerance, the dose is increased to 2 ml (200 mg) starting from the fourth injection. The treatment course is 25-30 injections.
If necessary, repeated courses may be conducted after 6 months.
For the formation of a bone callus, the treatment course lasts 3-4 weeks (10-14 injections every other day).

Composition per 1 ml:
Active ingredient: sodium chondroitin sulfate (calculated as dry substance) - 100 mg;
Excipients: water for injections - up to 1.0 ml.

A clear colorless solution or a solution with a slight yellowish tint.

• Increased sensitivity to the drug or its components.

• Bleeding and tendency to bleed, thrombophlebitis.

• Childhood age.

• Pregnancy and lactation period (data on the safety of the drug's use is currently unavailable).

Use in Pediatrics
There is currently no data on the efficacy and safety of chondroitin sulfate in children.

Allergic reactions may occur (skin itching, erythema, urticaria, dermatitis), hemorrhages at the injection site. In these cases, the medication is discontinued.

Currently, there have been no reported cases of chondroitin sulfate overdose.

During the course of treatment with the drug Khonsat®, caution should be exercised when using direct-acting anticoagulants simultaneously.
There may also be an enhancement of the effects of indirect anticoagulants, antiplatelet agents, and fibrinolytics, which necessitates more frequent monitoring of blood coagulation parameters during concurrent use.

High molecular weight mucopolysaccharide that affects metabolic processes in hyaline cartilage. The drug has chondroprotective properties, stimulates the regeneration of cartilage tissue, and has anti-inflammatory effects. It participates in the formation of the extracellular matrix of cartilage and bone tissue, improves phosphorus-calcium metabolism in cartilage tissue, inhibits enzymes that disrupt the structure and function of articular cartilage, and slows down the processes of cartilage degeneration. It stimulates the synthesis of proteoglycans, normalizes the metabolism of hyaline cartilage, and promotes the regeneration of cartilage surfaces and the joint capsule. It prevents the compression of connective tissue, increases the production of synovial fluid and the mobility of affected joints, reduces accompanying inflammation and pain, and helps decrease the need for NSAIDs. In cases of degenerative changes in cartilage tissue, it serves as a means of replacement therapy.
A positive effect is observed within 2-3 weeks after the start of the drug administration: joint pain decreases, clinical manifestations of reactive synovitis disappear, and the range of motion in affected joints increases. The therapeutic effect lasts for a long time (3-6 months) after the completion of the treatment course.

Chondroitin sulfate is easily absorbed after intramuscular administration. Significant concentrations are detected in the blood within 30 minutes after injection. The maximum concentration (Cmax) of chondroitin sulfate in plasma is reached after 1 hour, then gradually decreases over 2 days.
Chondroitin sulfate accumulates primarily in the cartilage tissue of the joints. The synovial membrane does not pose a barrier to the penetration of the drug into the joint cavity. After 15 minutes following intramuscular injection, chondroitin sulfate is found in the synovial fluid, then it penetrates into the articular cartilage, where its concentration peaks after 48 hours.

Store in a light-protected place at a temperature not exceeding 25°C. Do not freeze.